Outlook Therapeutics, Inc.
OTLK
$0.40
$0.0412.25%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -1.21M | -91.80K | 1.51M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.21M | -91.80K | 1.51M | -- | -- |
| Cost of Revenue | 3.66M | 6.90M | 7.57M | -- | 9.66M |
| Gross Profit | -4.87M | -6.99M | -6.07M | -- | -9.66M |
| SG&A Expenses | 8.61M | 10.33M | 9.68M | 7.98M | 11.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.28M | 17.22M | 17.25M | 12.39M | 21.61M |
| Operating Income | -13.48M | -17.31M | -15.75M | -12.39M | -21.61M |
| Income Before Tax | -23.06M | -14.85M | -20.15M | -46.35M | 17.38M |
| Income Tax Expenses | -- | -1.55M | -- | 2.80K | -- |
| Earnings from Continuing Operations | -23.06M | -13.29M | -20.15M | -46.36M | 17.38M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.06M | -13.29M | -20.15M | -46.36M | 17.38M |
| EBIT | -13.48M | -17.31M | -15.75M | -12.39M | -21.61M |
| EBITDA | -13.45M | -17.28M | -15.72M | -12.36M | -21.58M |
| EPS Basic | -0.38 | -0.28 | -0.55 | -1.50 | 0.72 |
| Normalized Basic EPS | -0.17 | -0.19 | -0.30 | -0.94 | 0.48 |
| EPS Diluted | -0.38 | -0.28 | -0.55 | -1.50 | 0.72 |
| Normalized Diluted EPS | -0.17 | -0.19 | -0.30 | -0.94 | 0.48 |
| Average Basic Shares Outstanding | 60.21M | 47.19M | 36.96M | 30.87M | 24.23M |
| Average Diluted Shares Outstanding | 60.21M | 47.19M | 36.96M | 30.87M | 24.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |